

資料47

図40




図40 小胞体ストレスによる細胞死に対する選別された化合物処理の影響 1  
 SH-SY5Y細胞を96 well plateにまき、24時間後、DMSOもしくは小胞体ストレス誘導剤であるthapsigargin(400nM)のみ、もしくはthapsigargin(400nM)と各種化合物を図に示す用量で処理した。48時間後、WST-8アッセイにより細胞のバイアピリティーを測定した。

# 資料48

図41




図41 小胞体ストレスによる細胞死に対する選別された化合物処理の影響 2  
 SH-SY5Y細胞を96 well plateにまき、24時間後、DMSOもしくは小胞体ストレス誘導剤であるthapsigargin(400nM)のみ、もしくはthapsigargin(400nM)と各種化合物を図に示す用量で処理した。48時間後、WST-8アッセイにより細胞のバイアピリティーを測定した。

## 資料49

図42




図42 小胞体ストレスによる細胞死に対する選別された化合物処理の影響 2  
SH-SY5Y細胞を96 well plateにまき、24時間後、DMSOもしくは小胞体ストレス誘導剤であるthapsigargin(400nM)のみ、もしくはthapsigargin(400nM)と各種化合物を図に示す用量で処理した。48時間後、WST-8アッセイにより細胞のバイアビリティを測定した。

書籍 特に該当なし

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nobumichi Ohoka, Keiichiro Okuhira, Hongyan Cui, Weijia Wu, Ryuichiro Sato, Mikihiro Naito, Tomoko Nishimaki-Mogami	HNF4 $\alpha$ Increases Liver-Specific Human ATP-Binding Cassette Transporter A1 Expression and Cholesterol Efflux to Apolipoprotein A-I in Response to Cholesterol Depletion	Arteriosclerosis, Thrombosis, and Vascular Biology	32 (4)	1005-14	2012
Keiichiro Okuhira, Nobumichi Ohoka, Kimie Sai, Tomoko Nishimaki-Mogami, Yukihiro Itoh, Minoru Ishikawa, Yuichi Hashimoto, Mikihiro Naito	Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein.	FEBS Letters	585 (8)	1147-52	2011

# Arteriosclerosis, Thrombosis, and Vascular Biology

JOURNAL OF THE AMERICAN HEART ASSOCIATION



## **HNF4 $\alpha$ Increases Liver-Specific Human ATP-Binding Cassette Transporter A1 Expression and Cholesterol Efflux to Apolipoprotein A-I in Response to Cholesterol Depletion**

Nobumichi Ohoka, Keiichiro Okuhira, Hongyan Cui, Weijia Wu, Ryuichiro Sato,  
Mikihiko Naito and Tomoko Nishimaki-Mogami

*Arterioscler Thromb Vasc Biol* 2012, 32:1005-1014: originally published online  
January 26, 2012

doi: 10.1161/ATVBAHA.111.238360

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association,  
7272 Greenville Avenue, Dallas, TX 72514

Copyright © 2012 American Heart Association. All rights reserved. Print ISSN: 1079-5642. Online  
ISSN: 1524-4636

The online version of this article, along with updated information and services, is  
located on the World Wide Web at:

<http://atvb.ahajournals.org/content/32/4/1005>

Data Supplement (unedited) at:

<http://atvb.ahajournals.org/content/suppl/2012/01/25/ATVBAHA.111.238360.DC1.html>

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular  
Biology is online at

<http://atvb.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters  
Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax:  
410-528-8550. E-mail:

[journalpermissions@lww.com](mailto:journalpermissions@lww.com)

Reprints: Information about reprints can be found online at

<http://www.lww.com/reprints>



# HNF4 $\alpha$ Increases Liver-Specific Human ATP-Binding Cassette Transporter A1 Expression and Cholesterol Efflux to Apolipoprotein A-I in Response to Cholesterol Depletion

Nobumichi Ohoka, Keiichiro Okuhira, Hongyan Cui, Weijia Wu, Ryuichiro Sato, Mikihiko Naito, Tomoko Nishimaki-Mogami

**Objective**—Hepatic ATP-binding cassette transporter A1 (ABCA1) plays the major role in maintaining plasma high-density lipoprotein levels by producing cholesterol-accepting nascent high-density lipoprotein, whereas peripheral ABCA1 is responsible for releasing cellular cholesterol. We previously reported that in rodents, cholesterol depletion reduces ABCA1 expression in peripheral but not hepatic cells by increasing a liver-specific *ABCA1* transcript via the sterol regulatory element-binding protein-2 system. However, the regulatory element is not conserved in humans. Here we investigated the mechanism of sterol-regulated human hepatic *ABCA1* gene expression.

**Methods and Results**—*ABCA1* mRNA variant *type L3* is a novel and human-liver-specific transcript accounting for  $\approx 25\%$  of total *ABCA1* mRNA in the liver and is induced by cellular cholesterol depletion. Specific knockdown or forced expression revealed that *type L3* produces functional ABCA1 protein in cholesterol efflux. We identified a regulatory enhancer element for *L3* expression lying within intron 3 of the human *ABCA1* gene, to which hepatocyte nuclear factor (HNF) 4 $\alpha$  binds in response to cholesterol depletion. HNF4 $\alpha$  knockdown abolished induction of liver-specific *L3* and *L2b* transcripts (and consequently the liver-type response of ABCA1 expression to cellular cholesterol status) and diminished cholesterol efflux activity.

**Conclusion**—These findings indicate that HNF4 $\alpha$  regulates human hepatic ABCA1 expression in response to cholesterol depletion. (*Arterioscler Thromb Vasc Biol.* 2012;32:1005-1014.)

**Key Words:** ABC transporter ■ gene expression ■ lipoproteins ■ cholesterol regulation

The ATP-binding cassette transporter A1 (ABCA1) is a plasma membrane transporter involved in cholesterol and phospholipid transport that plays a critical role in apolipoprotein A-I (apoA-I)-dependent biogenesis of high-density lipoprotein (HDL).<sup>1,2</sup> *ABCA1* gene mutations cause Tangier disease and familial HDL deficiencies characterized by a near absence of circulating HDL. The essential role of ABCA1 in HDL biogenesis was further demonstrated by studies that included ABCA1 overexpression and deletion in mice.<sup>3,4</sup>

Although ABCA1 is widely expressed in many tissues, gene-targeting studies in mice revealed that hepatic ABCA1 is responsible for approximately 80% of plasma HDL production.<sup>5</sup> Further studies suggested that the role of hepatic ABCA1 in maintaining plasma HDL levels is distinct from that of extrahepatic ABCA1.<sup>6</sup> Hepatic ABCA1 is critical for phospholipidating lipid-free apoA-I to generate cholesterol-poor early nascent HDL particles that in turn provide efficient cholesterol acceptors for peripheral cells, whereas ABCA1 in peripheral cells, such as macrophages and fibroblasts, mediates release of excess cellular cholesterol by generating

mature HDL particles,<sup>6</sup> probably in a sequential collaboration with ABCG1.<sup>7</sup> The proposed roles of hepatic and peripheral ABCA1 are consistent with a classic model of the reverse cholesterol transport pathway, in which HDL transports excess cholesterol from peripheral cells to the liver, where cholesterol can be converted into bile acids for excretion.<sup>8</sup>

Hepatic and peripheral ABCA1 are under distinct gene regulation. ABCA1 expression in peripheral cells is upregulated by a liver X receptor (LXR)-driven promoter system in response to cholesterol loading.<sup>9</sup> Conversely, cholesterol depletion or treatment of cells with statins that inhibit endogenous LXR ligand synthesis represses ABCA1 expression,<sup>10,11</sup> collectively indicating that cellular cholesterol homeostasis is stringently controlled by the LXR-ABCA1 pathway in peripheral cells. In contrast, hepatic *ABCA1* expression appears to be unaffected by sterols as suggested by the failure of cholesterol feeding of mice to elevate hepatic ABCA1 expression<sup>12,13</sup> and the inability of cholesterol depletion to repress expression.<sup>14-17</sup> In the preceding study using rodents,<sup>14</sup> we identified a liver-specific ABCA1 mRNA

Received on: September 6, 2011; final version accepted on: January 13, 2012.

From the Division of Biochemistry and Molecular Biology, National Institute of Health Sciences, Tokyo, Japan (N.O., K.O., H.C., W.W., M.N., T.N.-M.); Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan (R.S.).

The online-only Data Supplement is available with this article at <http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.111.238360/-DC1>.

Correspondence to Tomoko Nishimaki-Mogami, PhD, National Institute of Health Sciences, Kamiyoga 1-18-1, Setagaya-ku, Tokyo 158-8501, Japan. E-mail [mogami@nihs.go.jp](mailto:mogami@nihs.go.jp)

© 2012 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol* is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.111.238360

variant and a corresponding promoter element driven by sterol regulatory element-binding protein-2 (SREBP-2), a transcription factor activated by cellular cholesterol depletion, in addition to the peripheral-type *ABCA1* mRNA in the liver. Thus, cholesterol negatively and positively affects the liver-type SREBP-2 and peripheral-type LXR promoters, respectively, to control hepatic *ABCA1* expression. This SREBP-2- and LXR-driven dual promoter system appears to ensure that hepatic *ABCA1* expression is constant even under fluctuating cholesterol conditions and may be associated with *ABCA1*'s specific role in producing cholesterol acceptors in the reverse cholesterol transport pathway. Recently, microRNA-33 was shown to contribute to sterol-responsive *ABCA1* gene regulation. MicroRNA-33, located within the gene encoding *SREBPs*, inhibits the expression of *ABCA1* and makes a significant contribution to hepatic *ABCA1* and plasma HDL levels in mice.<sup>18,19</sup> Thus, multiple systems are likely to regulate hepatic *ABCA1* expression.

In human hepatoma HepG2 cells, *ABCA1* mRNA levels are slightly augmented on statin treatment,<sup>16,17</sup> which suggests that a liver-type regulation also occurs in humans. However, the SREBP-2 binding element (sterol regulatory element) in the liver-type promoter is not conserved in humans, suggesting that a different system may drive liver-specific *ABCA1* expression in humans. We report here that hepatocyte nuclear factor (HNF) 4 $\alpha$  regulates expression of liver-specific *ABCA1* transcripts in response to cholesterol depletion.


## Methods

An expanded Material and Methods section is available in the online-only Data Supplement. 5'-rapid amplification of cDNA end polymerase chain reaction (PCR), plasmid construction, cell culture, RNA extraction and quantitative real-time reverse transcription (RT)-PCR, Northern and Western blot analyses, RNA interference, reporter gene assays, cholesterol efflux assays, chromatin immunoprecipitation assay, electrophoretic mobility shift assay, avidin biotin-conjugated DNA assay, lentivirus infection, and statistical analysis are described in detail in the online-only Data Supplement.

## Results

### Expression of Liver-Specific *ABCA1* mRNA Variants in Human Liver Tissue and Hepatic Cells


To identify liver-specific *ABCA1* transcripts, we performed 5'-rapid amplification of cDNA end on total RNA extracted from human liver and identified 4 major bands (Figure 1A) containing 5 major *ABCA1* mRNA 5'-ends, which were designated *types L2a/b*, *L3*, and *L4a/b* (Figure 1B, bottom; details are shown in Figure 1A in the online-only Data Supplement), in addition to the previously described peripheral-type (type P) *ABCA1* transcript.<sup>14</sup> In contrast, peripheral THP-1 cells had only *type P* transcript. *Type L3* is a novel transcript that lacks exon 1/exon 2 and has a newly identified 303-bp sequence (exon L3) upstream of exon 3. Exon L3 appears to be unique to humans because of no homologous sequence in rodent *ABCA1* genes. *Type L2a* and *L2b* were homologous to rodent types *L* and *L'*, which we previously identified<sup>14</sup> (Figure 1A–1C in the online-only Data Supplement). *Type L4a* and *L4b* were similar to the human liver-type transcripts previously identified<sup>20</sup> and were expressed mainly in the liver (Figure 2 in the online-only Data



**Figure 1.** Identification of alternative ATP-binding cassette transporter A1 (*ABCA1*) transcripts in human liver. **A**, 5'-rapid amplification of cDNA end (RACE) was performed on total RNA extracted from 4 human livers and THP-1 cells treated with sterols (10  $\mu$ g/mL cholesterol plus 1  $\mu$ g/mL 25-hydroxycholesterol: sterols+ [S+] or compactin (50  $\mu$ mol/L with 40  $\mu$ mol/L mevalonate: sterols- [S-]) in the medium containing 10% delipidated serum for 16 hours. The amplified products were then subjected to electrophoresis in a 2% agarose gel. **B**, Structure of human *ABCA1* gene and major transcripts. **Black boxes** indicate exons (ex) for type P transcript. **Gray boxes** indicate liver-variant specific exons.

Supplement). *Type L2b* was less abundant compared with *type L2a*. Several minor transcripts, including those identified by Singaraja et al<sup>20</sup> and Cavelier et al,<sup>21</sup> are shown in Figure 1D in the online-only Data Supplement. All products identified here were spliced according to the GT-AG splicing rule.

Quantitative real-time RT-PCR (qRT-PCR) showed that newly identified *type L3* and *L2b* variants were expressed exclusively in the liver, whereas *type P* was expressed in various human tissues (Figure 2A). *Type L2a* levels were not measured because there were no variant-specific regions in this transcript. To determine the abundance of *type L3*, *L2b*, or *type P* relative to that of total *ABCA1* mRNA, we used variant-specific and universal RT-PCR probe/primers (Figure 1A in the online-only Data Supplement) and a standard curve based on serial dilution of cDNAs containing 2 target sequences for the qRT-PCR probe (*L3*/universal, *L2b*/universal, or *P*/universal, respectively). The *type L3* mRNA represented 26.2 $\pm$ 9.4% of total *ABCA1* mRNA in human liver RNA preparations (n=4), whereas *type P* and *type L2b* mRNA were estimated to be 33.4 $\pm$ 5.5% and 12.3 $\pm$ 4.8%, respectively, of total *ABCA1* mRNA, indicating that *type L3* is a novel and major *ABCA1* transcript expressed in human liver. *Type L3* was expressed in purified human hepatocytes at a higher level than that in the original total liver-cell preparations (Figure 2B).



**Figure 2.** ATP-binding cassette transporter A1 (ABCA1) mRNA expression profile. Shown is quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) analysis of total and variant ABCA1 mRNA levels in different human tissues (**A**); total liver cell preparations and purified hepatocytes originated from the same donors (**B**); and human hepatoma cell lines, THP-1 macrophage-like cells, and human livers (from 4 donors) (**C**). **A**, Multiple human tissue cDNA (BD multiple tissue cDNA) panel in which expression levels were normalized with a set of 4 housekeeping genes ( $\alpha$ -tubulin,  $\beta$ -actin, GAPDH, and rRNA S29). **C**, HepG2, Hep3B, JHH-5, and THP-1 cells were treated with sterols (10  $\mu$ g/mL cholesterol plus 1  $\mu$ g/mL 25-hydroxycholesterol: sterols+) or compactin (50 and 40  $\mu$ mol/L mevalonate: sterols-) for 16 hours. The mRNA levels were normalized with 18S rRNA. Values represent means  $\pm$  SD ( $n=3$ ) relative to the expression level in the liver (**A** and **B**) or JHH-5 cells (sterols-) (**C**) (expressed as the percentage of hepatic total ABCA1 mRNA).

*Type L3* and *L2b* mRNAs were highly expressed in human hepatoma cells (HepG2, Hep3B, and JHH-5<sup>22</sup>) at levels comparable to that in human liver tissues ( $n=4$ ) but undetectable in peripheral THP-1 cells (Figure 2C). The expression of *type L3* and *L2b* transcripts was augmented by cholesterol depletion in 3 hepatoma cell lines, as was rodent *type L*.<sup>14</sup> Conversely, in all cell lines tested, *type P* mRNA expression decreased in response to cholesterol depletion, as was reported previously.<sup>9</sup> *Type L4a* and *L4b* mRNA levels were extremely low and undetectable in all cell lines (data not shown). The total ABCA1 mRNA level in hepatic cell lines was either unaffected or mildly elevated by cholesterol depletion, whereas for peripheral THP-1 cells, total ABCA1 mRNA declined similarly to *type P* mRNA levels. These findings indicate that ABCA1 mRNA expression in human hepatoma cell lines is composed of sterol-repressed (*type L2* and *L3*) and sterol-augmented (*type P*) mRNA expression.

### Type L3 Is a Major ABCA1 Transcript Producing a Functional ABCA1 Protein


We investigated whether *type L3* mRNA encodes a functional ABCA1 protein using a short interfering RNA (siRNA) specific to the *type L3* transcript. In cholesterol-depleted JHH-5 and Hep3B cells, transfection of *type L3*-specific siRNA effectively diminished *type L3* mRNA expression without decreasing *type L2b* and *type P* mRNA levels (Figure 3A). Notably, specific knockdown of *type L3* mRNA caused a significant reduction in the total ABCA1 mRNA (Figure 3A) and protein levels (Figure 3B). To exclude off-target effects, we repeated the experiments using 3 other siRNAs specific to *type L3*, and we confirmed that these siRNAs also effectively diminished *type L3* mRNA and decreased total ABCA1

mRNA and protein expression (Figure 3D and Figure IV). Northern blot analysis confirmed the *L3* mRNA knockdown and an accompanying decrease in total ABCA1 mRNA band (Figure 3C). Furthermore, siRNA treatment caused an  $\approx 45\%$  decrease in apoA-I-dependent [<sup>3</sup>H]cholesterol efflux from JHH-5 cells under cholesterol-depleted conditions (Figure 3E). Also, 3 siRNAs to *type L3* significantly decreased the mass of free cholesterol efflux under normal culture conditions (Figure 3F). Although *type L3* ABCA1 mRNA lacks exon 2, which includes a known translation start codon, ATG<sup>9,23</sup> (Figure 1B and Figure III in the online-only Data Supplement), the *L3* transcript could be initiated at using the predicted start codon located at the 3'-end of exon L3 (Figures IC and III in the online-only Data Supplement). We constructed an expression vector of type L3 ABCA1 fusing green fluorescent protein to the C terminus and obtained JHH-5 cells stably expressing L3-ABCA1-green fluorescent protein, in which marked increases of ABCA1 expression and cholesterol efflux activity were observed (Figure 3G and 3H). Together, these results clearly show that *type L3* is a major transcript producing a functional ABCA1 protein in the liver.

### Identification of the Type L3 Promoter and Its Cholesterol-Responsive Enhancer Elements

To explore the mechanisms by which *type L3* transcripts were increased by cholesterol depletion, we searched for a possible promoter region for the *L3* transcript in the region upstream of the putative transcription initiation site (+1) for *type L3* mRNA (1010 or 4208 bp) (Figure 4A and 4B. *Luc1-Luc3*; Figure VI in the online-only Data Supplement). Although these regions did not have basal promoter activity and were unresponsive to cholesterol depletion in a luciferase assay, a reporter con-






**Figure 3.** Specific knockdown or forced expression of type L3 mRNA modulates total ATP-binding cassette transporter A1 (ABCA1) mRNA and protein expression and apolipoprotein A-I (apoA-I)-dependent cholesterol efflux. **A to F,** JHH-5 or Hep3B cells were transfected with either short interfering RNA (siRNA) against ABCA1 type L3 (**A, B, and E, #1; C to F, #1, 2, 3, or 4**) or a negative control (ctrl, con) siRNA. After 32 hours, cells were treated with compactin (50 and 40  $\mu\text{mol/L}$  mevalonate: sterols-) for 16 hours. **A,** Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) analysis of total and variant ABCA1 mRNA levels. Data were normalized with 18S rRNA and represent means  $\pm$  SD ( $n=3$ ). **C,** Northern blot analysis of total and variant ABCA1 mRNA levels using ABCA1 total and L3-specific probes. **B and D,** Immunoblot analysis of ABCA1 and the loading control anti- $\beta$ -actin. **Bar graphs** represent means  $\pm$  SD ( $n=4$ ). **E, F, and H,** Efflux of [<sup>3</sup>H]cholesterol (**E**) or cholesterol mass (**F and H**) from the cells to the media as described in Materials and Methods. **G and H,** JHH-5 cells stably expressing ABCA1 type L3-green fluorescent protein (GFP). **G,** Immunoblot analysis for ABCA1, GFP, and the loading control anti- $\beta$ -actin. **Bar graphs** represent means  $\pm$  SD ( $n=3$ ). **H,** Efflux of cholesterol mass from the cells to the media was determined. Data represent means  $\pm$  SD ( $n=3$ ). \* $P<0.05$  vs control siRNA-transfected (**A-F**) or mock-transfected (**H**) cells.

struct containing an element from +426 to +480 did show basal transcriptional activity and caused mild activation on cholesterol depletion (Figure 4B, *Luc5*), albeit at a level that is likely insufficient to produce a full response to sterols.

The promoter activities of several genes are often regulated by distal enhancers. Sequence alignment of 5 mammalian *ABCA1* genes identified a highly conserved region in intron 3 (positioned between +3103 and +3378 in humans) (Figure 4A; Figures VI and VII in the online-only Data Supplement). Therefore, we examined whether this region functions as an enhancer for the *ABCA1* type L3 promoter by inserting the conserved region of intron 3 into the 3'-end of the poly A site (Figure 4A). We found that insertion of this region effectively enhanced type L3 promoter activity, and this activity was

further amplified by cholesterol depletion (Figure 4C, *Luc7*). Furthermore, introducing this region into a reporter plasmid driven by the *SV40* promoter instead of the type L3 promoter potentiated both basal promoter activity and a sterol response (Figure 4D, *Luc9*). These results suggest that the conserved region in *ABCA1* intron 3 functions as a distal enhancer of the type L3 promoter that could be responsible for upregulation under sterol-depleted conditions.


To identify the sterol-responsive elements in this enhancer region, we performed a deletion analysis in this region. Deleting the 5'-end up to +3171 enhanced the promoter activity and sterol-mediated response (*Luc10*), whereas further deletion greatly diminished these effects (Figure 4E, *Luc11-Luc14*). The region between +3172 and +3183



**Figure 4.** Identification of type L3 promoter and its cholesterol-responsive enhancer elements. **A**, Genomic structure of the promoter region of type L3 transcript (top and middle rows) and the structure of the luciferase (Luc) reporter constructs (bottom row). The transcription start site of type L3 is indicated as +1. The exons (ex) are represented by thick boxes. **B** to **E**, JHH-5 cells were transfected with the indicated reporter plasmids and control renilla luciferase plasmid-SV40. After 30 hours, cells were treated with sterols (10  $\mu$ g/mL cholesterol plus 1  $\mu$ g/mL 25-hydroxycholesterol: sterols+) or compactin (50  $\mu$ mol/L, with 40  $\mu$ mol/L mevalonate: sterols-) for 16 hours. The firefly luciferase activity in cell lysates was measured and normalized with Renilla luciferase activity. The data represent means  $\pm$  SD (n=3). **E**, top panel, Putative sterol-response element sequence in intron 3. P-Box indicates a palindromic sequence box; hepatocyte nuclear factor (HNF) 1, a putative HNF1-binding site; HNF4, a putative HNF4-binding site.

contains a palindromic sequence box (P-Box) (Figure 4E, upper scheme). In a similar fashion, 3'-end deletions up to +3260 enhanced the promoter activity and the response to sterol depletion (Luc16), whereas deletion up to +3247 (Luc17) markedly decreased the response, and further deletion up to +3230 (Luc18) completely abolished these effects.

Accordingly, a reporter containing the region from +3172 to +3259 showed a strong response to sterol depletion (Figure 4E, Luc19). Within this responsive region, deletion of either the 3'-end up to +3247 or the region between +3229 and +3241 significantly repressed the sterol-mediated response (Figure 4E, Luc20, Luc21). These results suggest that the P-box and the 2




**Figure 5.** Hepatocyte nuclear factor (HNF) 4 $\alpha$  regulates ATP-binding cassette transporter A1 (ABCA1) type L3 promoter-enhancer activity by binding to the distal enhancer element. **A** to **D**, JHH-5 (**A**, **B**, and **D**) or HepG2 (**C**) cells were transfected with the indicated reporter plasmids and control plasmid control renilla luciferase plasmid-SV40 in the absence or presence of HNF4 $\alpha$  or HNF1 $\alpha$  expression vectors. **A**, **C**, and **D**, After 48 hours, the firefly luciferase (Luc) activity in cell lysates was measured and normalized with *Renilla* luciferase activity. **B**, After 30 hours of transfection, the cells were treated under sterols+ or sterols- conditions as in Figure 2C for 16 hours. DN indicates dominant negative. Data represent means  $\pm$  SD (n=3). SV40 indicates SV40 promoter. **E** and **F**, JHH-5 cells were treated under sterols+ or sterols- conditions for 16 hours. **E**, Cells were subjected to chromatin immunoprecipitation (IP) assay using the indicated antibodies or control IgG. The immunoprecipitated region containing HNF4 $\alpha$ -response elements within the intron 3 enhancer region was amplified with polymerase chain reaction (PCR) using specific primers as described in Materials and Methods. The amplified PCR products were subjected to electrophoresis in a 2% agarose gel. Input indicates that genomes extracted from 2% of total lysates were amplified with PCR. **F**, The cell lysates were subjected to avidin biotin-conjugated DNA assays using 2 biotin-conjugated nucleotides (#1 or #2) as indicated in the top panel and, together with an aliquot of the lysates (input), immunoblotted (IB) with anti-HNF4 $\alpha$  antibody. The arrow and asterisk indicate HNF4 $\alpha$  protein and nonspecific bands, respectively.

elements (+3247 to +3259, +3229 to +3241) are required for the sterol-mediated response in the distal enhancer region in *ABCA1* intron 3. A homology search detected consensus binding sequences for various transcription factors, suggesting that these elements (+3230/+3243 and +3224/+3256) could be binding sites for liver-enriched transcription factors such as HNF1 and HNF4, respectively (<http://tfbind.ims.u-tokyo.ac.jp/>; Figure 4E, upper scheme).

### HNF4 $\alpha$ Regulates Type L3 Promoter Activity Through Binding to the Distal Enhancer Elements

The role of liver-specific transcription factors HNF1 $\alpha$  and HNF4 $\alpha$  in the sterol-responsive distal enhancer activity within *ABCA1* intron 3 was investigated. Whereas HNF4 $\alpha$  expression effectively augmented type L3 promoter-enhancer activity in a distal enhancer region-dependent manner,

HNF1 $\alpha$  produced only minimal enhancement (Figure 5A). Expression of a dominant negative form of HNF4 $\alpha$  lacking the AF-2 domain repressed its promoter-enhancing activity, especially under cholesterol-depleted conditions (Figure 5B). HNF4 $\alpha$  expression also augmented the activity of a SV40 promoter-driven reporter gene containing the *ABCA1* enhancer region (Figure 5C, Luc22) but did not activate a construct that lacked the putative HNF4-binding site (Luc23). Deletion of the P-box (Luc24) or putative HNF1 site (Luc25) did not affect this HNF4 $\alpha$ -mediated augmentation. In addition, the activity of a reporter gene containing 4 tandem repeats of the HNF4-response element was enhanced by HNF4 $\alpha$  expression (Luc26). These results indicate that the HNF4-element, but not the P-box nor putative HNF1-binding site, is critical for HNF4 $\alpha$ -mediated activation of *ABCA1* expression.



**Figure 6.** Hepatocyte nuclear factor (HNF) 4 $\alpha$  regulates ATP-binding cassette transporter A1 (ABCA1) expression in human hepatoma cells by inducing liver-specific ABCA1 L3 and L2b mRNA in response to sterol depletion. **A to C**, JHH-5 cells were transfected with either short interfering RNA (siRNA) against HNF4 $\alpha$  L3 (#1–#3) or a negative control (ctrl) siRNA. After 32 hours, the cells were treated under sterols+ or sterols– (**A** and **B**) or sterol– (**C**) conditions for 16 hours. **A**, Quantitative real-time reverse transcription–polymerase chain reaction analysis of total and variant ABCA1 and HNF4 $\alpha$  mRNA expression. Data were normalized with 18S rRNA and represent means $\pm$ SD (n=3). \* $P$ <0.05 vs sterol+ control, # $P$ <0.05 vs sterol– control. One of the HNF4 $\alpha$  siRNAs (#1) induced a moderate increase in type P mRNA, probably because of an off-target effect. **B** and **C**, Immunoblot analysis for ABCA1, HNF-4 $\alpha$  and the loading control  $\beta$ -actin. **C**, Cholesterol efflux to the media was determined as described in Materials and Methods. The data represent means $\pm$ SD (n=3) \* $P$ <0.05 vs control siRNA-transfected cells.

We performed a chromatin immunoprecipitation assay to investigate whether endogenous HNF4 $\alpha$  protein associates with chromatin via this putative HNF4-binding site. Clear bands were detected when chromatin from cholesterol-depleted JHH-5 cells was immunoprecipitated with antibodies against HNF4 $\alpha$ , indicating that a tight association of endogenous HNF4 $\alpha$  protein with the conserved intron 3 region was induced by cholesterol depletion (Figure 5E). Additionally, an in vitro DNA binding assay confirmed the association of HNF4 $\alpha$  with this site. Endogenous HNF4 $\alpha$  in lysates of cholesterol-depleted cells reacted with biotin-conjugated oligodeoxynucleotides corresponding to the ABCA1 region from +3223 to +3262 that includes the HNF4-response element (#1), but not oligonucleotides that

lacked this element (#2) (Figure 5F). Furthermore, electrophoretic mobility shift assay also confirmed the association of HNF4 $\alpha$  with this binding site (Figure VIII in the online-only Data Supplement). These results indicate that the putative HNF4-binding site on ABCA1 intron 3 is authentic.

### HNF4 $\alpha$ Is Required for Expression of Liver-Specific ABCA1 mRNA and Protein in Response to Sterol Depletion

The role of HNF4 $\alpha$  in liver-type ABCA1 mRNA variant expression was investigated using siRNA knockdown. In JHH-5 cells, 3 siRNAs against HNF4 $\alpha$  effectively reduced HNF4 $\alpha$  mRNA and protein expression (Figure 6A and 6B). HNF4 $\alpha$  knockdown resulted in the reduced expression of

*type L3* and also *type L2b* but not *type P* transcripts under sterol-depleted conditions (Figure 6A, black bars). Consistently, expression of total *ABCA1* mRNA and protein was reduced by HNF4 $\alpha$  knockdown under sterol-depleted conditions (Figure 6A and 6B). Reduction of *type L3* and total *ABCA1* mRNA was also confirmed by Northern blot (Figure V in the online-only Data Supplement). In the presence of cholesterol, however, HNF4 $\alpha$  knockdown did not affect the expression of *ABCA1* transcripts (Figure 6A, white bars), although 1 siRNA (#1) induced *type P* and total *ABCA1* mRNA expression probably because of an off-target effect. Similar results were obtained with another human hepatic cell line Hep3B (Figure IXA and IXB in the online-only Data Supplement). In agreement with these results, HNF4 $\alpha$  knockdown in JHH-5 and Hep3B cells reduced apoA-I-mediated cholesterol efflux under cholesterol-depleted conditions (Figure 6C; Figure IXC in the online-only Data Supplement). Conversely, forced expression of HNF4 $\alpha$  increased the level of *type L3* and *L2b* transcripts, leading to a significant increase in total *ABCA1* mRNA expression and apoA-I-mediated cholesterol efflux (Figure X in the online-only Data Supplement). We also confirmed that HNF4 $\alpha$  knockdown markedly reduced the *type L3* promoter-enhancer activity (Figure XI A in the online-only Data Supplement) and the HNF4-binding site-dependent intron 3 enhancer activity (Figure XI B in the online-only Data Supplement) in sterol depleted cells but did not efficiently modulate the expression of *LXR $\alpha$* , *LXR $\beta$* , and *micro-RNA-33*, which are regulatory genes of *ABCA1* transcript (Figure XI in the online-only Data Supplement). These results indicate that HNF4 $\alpha$  is required for liver-specific *ABCA1* transcript (*L3* and *L2b*) expression and liver-type response of *ABCA1* mRNA and protein expression on cholesterol depletion.

### Discussion

The liver is the major source of apoA-I, and hepatic *ABCA1* is responsible for producing the majority of plasma HDL.<sup>5,6</sup> Hepatic *ABCA1* has a specific role in producing early nascent HDL particles,<sup>6</sup> and its genetic regulation is distinct from extrahepatic *ABCA1*.<sup>14</sup> In this study, we investigated the regulation of *ABCA1* expression in human liver cells and discovered a liver-specific regulatory system in humans. Among the liver-specific variants (*types L2a/b*, *L3*, *L4a/b*), *type L3* is a novel *ABCA1* transcript containing a human-specific exon L3 and is a major transcript accounting for  $\approx 25\%$  of total *ABCA1* mRNA in human liver.

The *ABCA1* protein translated from *type L3* transcript lacks the amino-terminal 21 amino acids, because the first ATG codon resides in the 3'-end of exon L3 (Figure III in the online-only Data Supplement). Although early studies showed that an *ABCA1* expression construct lacking the 60 amino-terminal amino acids does not produce a functional protein in cells,<sup>24</sup> specific siRNAs against *type L3* efficiently reduced *ABCA1* protein and cholesterol efflux. Moreover, transfection of L3-*ABCA1* expression vector into JHH-5 cells augmented *ABCA1* protein and cholesterol efflux activity, demonstrating that the L3-derived *ABCA1* variant protein is stable and functionally active.

### HNF4 $\alpha$ Regulates Hepatic *ABCA1* Gene Expression in Humans

When cellular cholesterol is depleted, the liver-specific *type L3* and *L2b* transcripts are induced and positively regulate *ABCA1* protein expression (Figure XIII in the online-only Data Supplement). We previously discovered that SREBP-2, a transcription factor activated on cellular cholesterol depletion,<sup>25</sup> upregulates the rodent liver-type (*type L*) *ABCA1* promoter.<sup>14</sup> However, the SREBP-2 binding element (sterol regulatory element) in the rat promoter is not conserved in humans (Figure XIV A in the online-only Data Supplement), and the human *type L2* promoter containing this region is not activated by cholesterol depletion (Figure XIV B in the online-only Data Supplement). In humans, we found a critical role of the liver-enriched transcription factor HNF4 $\alpha$  in hepatic *ABCA1* expression. Knockdown of HNF4 $\alpha$  abolished inductions of *L3* and *L2b* mRNA and, conversely, forced expression of HNF4 $\alpha$  in JHH-5 cells increased them. Altered *L3* and *L2b* mRNA levels led to substantial changes in total *ABCA1* mRNA and protein expression and in cholesterol efflux activity. Thus, HNF4 $\alpha$  is required for the induction of liver-specific *ABCA1* transcripts, including *types L3* and *L2b*, and thereby modulates *ABCA1* expression and HDL generation.

We identified a regulatory enhancer element for *L3* expression lying within intron 3 of the human *ABCA1* gene, to which HNF4 $\alpha$  binds and at which HNF4 $\alpha$  augments the L3 promoter-enhancer activity in response to cholesterol depletion. Because HNF4 $\alpha$  expression was increased on cholesterol depletion and HNF4 $\alpha$  knockdown abolished the *L3* and *L2b* induction, it is likely that the HNF4 $\alpha$  level or activity (via dephosphorylation<sup>26</sup>) determine the sterol-responsive *L3* and *L2b* expression. However, it is more likely that along with HNF4 $\alpha$ , several transcription factor(s) cooperatively regulate the *L2* and *L3* expression, because we identified several elements (and region) responding to cholesterol depletion in the intron 3-enhancer and the L3 promoter (Figure 4E). In addition, in human JHH-5 cells, SREBP-2 knockdown partly diminished the *L3* and *L2b* induction on sterol depletion (Figure XV in the online-only Data Supplement). Thus, SREBP2 partially regulates human hepatic *ABCA1* expression through distinct mechanism from that in rodents. Although decreased HNF4 $\alpha$  expression (Figure XV in the online-only Data Supplement) may be responsible for this effect, it is possible that SREBP-2 directly (via some unknown sterol regulatory element) or indirectly (via interaction with HNF4 $\alpha$ ) regulates *L3* and *L2b* mRNA expression. Decreased *type P* mRNA expression by SREBP-2 knockdown is probably due to the decreased supply of endogenous ligands for LXR.<sup>27</sup>

HNF4 $\alpha$  knockdown resulted in the reduced expression of *types L3* and *L2b* but not *type P*. Although we have confirmed that neither LXR regulating *type P* promoter nor microRNA-33 regulating *ABCA1* mRNA stability was affected by HNF4 $\alpha$  knockdown, further investigation on chromatin-loop or transcription factors is needed to understand the mechanism.

Because the HNF4 binding site located in *ABCA1* intron 3 is conserved among mammals (Figure III in the online-only Data Supplement), HNF4 $\alpha$  may also regulate the liver-type

ABCA1 transcript(s) in rodents. However, we could not confirm this because of the unavailability of variant-specific primers for rodent *type L* mRNA that corresponds to human *type L2a*. In addition, a rodent variant corresponding to human *type L3* may not be expressed in rodent liver because exon L3 is not conserved in rodents. Studies have shown that acute loss of HNF4 $\alpha$  (for 6–7 days) in mouse liver reduced ABCA1 mRNA expression,<sup>28</sup> although Cre-loxP knockdown did not affect the level.<sup>29</sup> Thus, the detailed mechanisms that regulate liver-specific ABCA1 gene expression may differ between humans and rodents. However, hepatic ABCA1 gene expression is ensured by stimulating liver-specific systems on cholesterol depletion, a response that is conserved among humans, mice, and rats.

HNF4 $\alpha$  is a highly conserved member of the nuclear receptor superfamily.<sup>26</sup> Loss-of-function mutations in the human HNF4 $\alpha$  gene cause the disorder maturity onset diabetes of the young (MODY1).<sup>26</sup> HNF4 $\alpha$  is required for early liver development and expression of many liver-specific genes, including those involved in lipoprotein and cholesterol/bile acid metabolism.<sup>26,30</sup> For example, HNF4 $\alpha$  regulates expression of microsomal triglyceride transfer protein, apolipoprotein B, CII, and CIII, genes involved in very-low-density lipoprotein production<sup>31</sup>; cholesterol 7 $\alpha$ -hydroxylase (CYP7A1), the rate-limiting enzyme of bile acid biosynthesis from cholesterol<sup>26,30</sup>; and ABCG5/ABCG8, transporters involved in cholesterol/sterol excretion from the liver.<sup>32</sup> Together with these genes, HNF4 $\alpha$ -regulated ABCA1 gene expression may cooperatively control hepatic cholesterol elimination to maintain cholesterol homeostasis. A recent study has shown that HNF4 $\alpha$ -siRNA knockdown in mouse liver reduces expression of many lipid metabolism genes, including ABCA1, leading to decreases in HDL and very-low-density lipoprotein in plasma.<sup>28</sup>

### Dual System Regulates Human Hepatic ABCA1 Gene Expression in Response to Sterols

In the model of reverse cholesterol transport pathway, the liver plays a role in excreting cholesterol transported from peripheral tissues.<sup>8</sup> The liver is also the major site of production of HDL, and hepatic ABCA1 is responsible for maintaining plasma HDL by producing a precursor form of HDL,<sup>5,6</sup> which could accept cholesterol from peripheral cells. When cholesterol accumulates in the liver, the *type P* ABCA1 transcript is induced by the LXR promoter.<sup>14</sup> However, this rise is counterbalanced by the reduced expression of *liver-type L3* and *L2a/b* transcripts (Figure XIII in the online-only Data Supplement). The dual system may prevent overshooting ABCA1 expression and retransport of cholesterol to peripheral tissues. On cholesterol depletion, *type P* ABCA1 expression is reduced, but enhanced *type L3* and *L2a/b* expression may compensate for this reduction. Thus, the dual system ensures constant expression of ABCA1 and HDL production in the human liver even under fluctuating cholesterol conditions. Recent studies show that *microRNA-33* regulates hepatic ABCA1 expression and plasma HDL levels in mice<sup>18,19</sup> ABCA1 expression also undergoes posttranslational regulation.<sup>33</sup> Because hepatic ABCA1 plays the major role in maintaining plasma HDL levels,<sup>5</sup> it seems reasonable

that hepatic ABCA1 expression would be stringently regulated by multiple sterol-responsive systems.

### Regulation of Human Hepatic ABCA1 as a Novel Strategy to Prevent Atherosclerosis

Statins are widely used to treat hypercholesterolemia and raise plasma HDL cholesterol independently of reducing low-density lipoprotein cholesterol.<sup>34</sup> Several studies have shown that statins upregulate hepatic ABCA1 mRNA expression in human hepatoma cells and mouse liver,<sup>15–17</sup> whereas statins repress peripheral ABCA1 mRNA expression by depleting endogenous LXR ligands.<sup>10,11</sup> Our findings indicate that the liver-specific ABCA1 variants, including *type L3* and *L2a/b* (or *L* in rodents), are responsible for statin-induced ABCA1 expression and may be associated with increased plasma HDL levels.

Our current study clarified for the first time a mechanism by which human hepatic ABCA1 expression is regulated. HDL cholesterol levels are inversely correlated with cardiovascular risk. Because hepatic ABCA1 has the largest impact on plasma HDL levels<sup>5,6</sup> and is the most promising therapeutic target, our findings provide a basis for developing novel drugs to control plasma HDL levels and prevent atherosclerosis.

### Acknowledgments

We are especially grateful to Dr Seishi Nagamori for providing JHH-5 cells.

### Sources of Funding

This work was supported in part by a grant from the Japan Health Sciences Foundation and a Grant-in Aid for Scientific Research from Japan Society for the Promotion of Science.

### Disclosures

None.

### References

1. Yokoyama S. ABCA1 and biogenesis of HDL. *J Atheroscler Thromb*. 2006;13:1–15.
2. Attie AD. ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. *Trends Biochem Sci*. 2007;32:172–179.
3. Joyce C, Freeman L, Brewer HB Jr, Santamarina-Fojo S. Study of ABCA1 function in transgenic mice. *Arterioscler Thromb Vasc Biol*. 2003;23:965–971.
4. Aiello RJ, Brees D, Francone OL. ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. *Arterioscler Thromb Vasc Biol*. 2003;23:972–980.
5. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. *J Clin Invest*. 2005;115:1333–1342.
6. Singaraja RR, Van Eck M, Bissada N, Zimetti F, Collins HL, Hildebrand RB, Hayden A, Brunham LR, Kang MH, Fruchart JC, Van Berkel TJ, Parks JS, Staels B, Rothblat GH, Fievat C, Hayden MR. Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. *Circulation*. 2006;114:1301–1309.
7. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. *Arterioscler Thromb Vasc Biol*. 2010;30:139–143.
8. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. *J Lipid Res*. 1968;9:155–167.
9. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. *J Biol Chem*. 2000;275:28240–28245.



10. Suzuki S, Nishimaki-Mogami T, Tamehiro N, Inoue K, Arakawa R, Abe-Dohmae S, Tanaka AR, Ueda K, Yokoyama S. Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism. *Arterioscler Thromb Vasc Biol*. 2004;24:519–525.
11. Wong J, Quinn CM, Brown AJ. Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. *Arterioscler Thromb Vasc Biol*. 2004;24:2365–2371.
12. Hoekstra M, Out R, Kruijt JK, Van Eck M, Van Berkel TJ. Diet induced regulation of genes involved in cholesterol metabolism in rat liver parenchymal and Kupffer cells. *J Hepatol*. 2005;42:400–407.
13. Engelking LJ, Kuriyama H, Hammer RE, Horton JD, Brown MS, Goldstein JL, Liang G. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. *J Clin Invest*. 2004;113:1168–1175.
14. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, Nagao T, Nishimaki-Mogami T. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. *J Biol Chem*. 2007;282:21090–21099.
15. Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A. Effects of pravastatin on the expression of ATP-binding cassette transporter A1. *The J Pharmacol Exp Ther*. 2004;311:420–425.
16. Sone H, Shimano H, Shu M, Nakakuki M, Takahashi A, Sakai M, Sakamoto Y, Yokoo T, Matsuzaka K, Okazaki H, Nakagawa Y, Iida KT, Suzuki H, Toyoshima H, Horiuchi S, Yamada N. Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages. *Biochem Biophys Res Commun*. 2004;316:790–794.
17. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. *Biochem Biophys Res Commun*. 2004;324:835–839.
18. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. *Science*. 2010;328:1566–1569.
19. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis. *Science*. 2010;328:1570–1573.
20. Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, Tan B, Brooks-Wilson A, Kwok A, Bissada N, Yang YZ, Liu G, Tafuri SR, Fievret C, Wellington CL, Staels B, Hayden MR. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoA1-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. *J Biol Chem*. 2001;276:33969–33979.
21. Cavalier LB, Qiu Y, Bielicki JK, Afzal V, Cheng JF, Rubin EM. Regulation and activity of the human ABCA1 gene in transgenic mice. *J Biol Chem*. 2001;276:18046–18051.
22. Fujise K, Nagamori S, Hasumura S, Homma S, Sujino H, Matsuura T, Shimizu K, Niiya M, Kameda H, Fujita K, et al. Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. *Hepato-gastroenterology*. 1990;37:457–460.
23. Santamarina-Fojo S, Peterson K, Knapper C, Qiu Y, Freeman L, Cheng JF, Osorio J, Remaley A, Yang XP, Haudenschild C, Prades C, Chimini G, Blackmon E, Francois T, Duverger N, Rubin EM, Rosier M, Deneffe P, Fredrickson DS, Brewer HB Jr. Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. *Proc Natl Acad Sci USA*. 2000;97:7987–7992.
24. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. *J Biol Chem*. 2000;275:33053–33058.
25. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. *Cell*. 2006;124:35–46.
26. Gonzalez FJ. Regulation of hepatocyte nuclear factor 4  $\alpha$ -mediated transcription. *Drug Metab Pharmacokinet*. 2008;23:2–7.
27. Wong J, Quinn CM, Brown AJ. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. *Biochem J*. 2006;400:485–491.
28. Yin L, Ma H, Ge X, Edwards PA, Zhang Y. Hepatic hepatocyte nuclear factor 4 $\alpha$  is essential for maintaining triglyceride and cholesterol homeostasis. *Arterioscler Thromb Vasc Biol*. 2011;31:328–336.
29. Holloway MG, Miles GD, Dombkowski AA, Waxman DJ. Liver-specific hepatocyte nuclear factor-4 $\alpha$  deficiency: greater impact on gene expression in male than in female mouse liver. *Mol Endocrinol*. 2008;22:1274–1286.
30. Crestani M, De Fabiani E, Caruso D, Mitro N, Gilardi F, Vigil Chacon AB, Patelli R, Godio C, Galli G. LXR (liver X receptor) and HNF-4 (hepatocyte nuclear factor-4): key regulators in reverse cholesterol transport. *Biochem Soc Trans*. 2004;32:92–96.
31. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, Fraenkel E, Bell GI, Young RA. Control of pancreas and liver gene expression by HNF transcription factors. *Science*. 2004;303:1378–1381.
32. Sumi K, Tanaka T, Uchida A, Magoori K, Urashima Y, Ohashi R, Ohguchi H, Okamura M, Kudo H, Daigo K, Maejima T, Kojima N, Sakakibara I, Jiang S, Hasegawa G, Kim I, Osborne TF, Naito M, Gonzalez FJ, Hamakubo T, Kodama T, Sakai J. Cooperative interaction between hepatocyte nuclear factor 4  $\alpha$  and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. *Mol Cell Biol*. 2007;27:4248–4260.
33. Okuhira K, Fitzgerald ML, Tamehiro N, Ohoka N, Suzuki K, Sawada J, Naito M, Nishimaki-Mogami T. Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. *J Biol Chem*. 2010;285:16369–16377.
34. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. *JAMA*. 2007;297:499–508.



## Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein

Keiichiro Okuhira<sup>a</sup>, Nobumichi Ohoka<sup>a</sup>, Kimie Sai<sup>a</sup>, Tomoko Nishimaki-Mogami<sup>a</sup>, Yukihiro Itoh<sup>b</sup>, Minoru Ishikawa<sup>b</sup>, Yuichi Hashimoto<sup>b</sup>, Mikihiro Naito<sup>a,\*</sup>

<sup>a</sup>Division of Biochemistry and Molecular Biology, National Institute of Health Sciences, Japan

<sup>b</sup>Institute of Molecular and Cellular Biosciences, The University of Tokyo, Japan

### ARTICLE INFO

#### Article history:

Received 12 January 2011

Revised 7 March 2011

Accepted 8 March 2011

Available online 15 March 2011

Edited by Noboru Mizushima

#### Keywords:

Cellular inhibitor of apoptosis protein 1

Cellular retinoic acid binding protein-II

Protein knockdown

Ubiquitin

Proteasome

### ABSTRACT

**Manipulation of protein stability with small molecules is a challenge in the field of drug discovery. Here we show that cellular retinoic acid binding protein-II (CRABP-II) can be specifically degraded by a novel compound, SNIPER-4, consisting of (–)-N-[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butyl]-L-leucine methyl ester and all-trans retinoic acid that are ligands for cellular inhibitor of apoptosis protein 1 (cIAP1) and CRABP-II, respectively. Mechanistic analysis revealed that SNIPER-4 induces cIAP1-mediated ubiquitylation of CRABP-II, resulting in the proteasomal degradation. The protein knockdown strategy employing the structure of SNIPER-4 could be applicable to other target proteins.**

© 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

### 1. Introduction

The ubiquitin–proteasome system (UPS) plays a crucial role in selective degradation of proteins, which is involved in the regulation of cell cycle, proliferation, differentiation and cell death [1–3]. In the UPS, the target protein is poly-ubiquitylated by the sequential action of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin-ligase (E3), where E3 determines the specificity for the target protein in many cases. The poly-ubiquitylated proteins are degraded by proteasome. Inappropriate regulation of the UPS results in an accumulation or depletion of certain proteins, which results in a variety of diseases such as cancer, cachexia, neurodegenerative disorders and malformation [4–8]. To reduce a pathogenic protein in cells, it is useful to take advantage of the UPS since it is a highly specific system to


target a certain protein for degradation, and the degradation occurs very quickly. However, few studies have been reported so far on the specific degradation of target proteins utilizing the UPS [9].

We previously reported that a class of small molecules, represented by (–)-N-[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butyl]-L-leucine methyl ester (MeBS), destabilize cellular inhibitor of apoptosis protein 1 (cIAP1), a ubiquitin-ligase (E3) belonging to IAP (inhibitor of apoptosis protein) family [10–12], and sensitize cancer cells to apoptosis induced by anti-cancer drugs and death receptor ligation [13–16]. MeBS directly interacts with cIAP1 at its BIR3 domain and induces auto-ubiquitylation of cIAP1 depending on its RING domain, resulting in the proteasomal degradation of cIAP1. Structure–activity relationship study indicated that analogs with a carboxyl-ester reduce the amount of cIAP1 even though the methyl group is substituted to other residues, and other modifications of MeBS seriously affected the activity [13]. Based on these observations, we hypothesized that the methyl group can be substituted to a ligand for a target protein without ablating the ubiquitin ligase activity of cIAP1. The hybrid molecule consisting of MeBS and the ligand would be able to cross-link cIAP1 and the target protein, to induce ubiquitylation and proteasomal degradation of the target protein. As a proof-of-concept study, we designed and synthesized a series of hybrid compounds consisting of MeBS and all-trans retinoic acid (ATRA), and found that they

**Abbreviations:** cIAP1, cellular inhibitor of apoptosis protein 1; MeBS, (–)-N-[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butyl]-L-leucine methyl ester; ATRA, all-trans retinoic acid; CRABP, cellular retinoic acid binding protein

\* Corresponding author. Address: Division of Biochemistry and Molecular Biology, National Institute of Health Sciences, 1-18-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan. Fax: +81 3 3707 6950.

E-mail address: [miki-naito@nihs.go.jp](mailto:miki-naito@nihs.go.jp) (M. Naito).



**Fig. 1.** Structure and protein knockdown activity of SNIPERs. (A) Structures of MeBS (top), SNIPER-2 (middle) and SNIPER-4 (bottom). (B) Reduction of endogenous CRABP-II and cIAP1 by SNIPER-2. (C) SNIPER-4 reduces endogenous CRABP-II but not cIAP1. (D) Inhibition of the SNIPER-mediated protein knockdown by a proteasome inhibitor, MG132. Human primary fibroblasts (B), HT1080 (C) or HT1080 cells expressing FLAG-CRABP-II (D) were incubated with 10  $\mu$ M of indicated compounds for 6 h. Cells were pre-treated with 10  $\mu$ M of MG132 for 30 min in (D). Shown are immunoblots of cell lysates stained with indicated antibodies.

induce the proteasomal degradation of CRABP-II, an ATRA-binding protein [17]. Thus, selective degradation of target protein (protein knockdown) can be attained by the hybrid molecules that cross-link the target protein and cIAP1.

The hybrid molecule we have developed previously [17], which we named SNIPER (Specific and Non-genetic IAP-dependent Protein ERaser)-2 in this study, however, has two major downsides that would be unfavorable for protein knockdown: (1) SNIPER-2 causes a simultaneous degradation of cIAP1 with the target protein CRABP-II, which may make the protein knockdown unsustainable, and (2) SNIPER-2 contains an ester-bond which is vulnerable to hydrolysis. To overcome these issues, we here developed SNIPER-4, in which the ester-bond is substituted to amide-bond, and found that the SNIPER-4 induces specific and sustained degradation of CRABP-II without inducing cIAP1 degradation. We also investigated biochemical mechanisms by which SNIPERs target CRABP-II for degradation, and demonstrate that SNIPERs induce the ubiquitylation of CRABP-II, which is mediated by cIAP1 but not by XIAP.

## 2. Materials and methods

### 2.1. Reagents and plasmids


MeBS was kindly provided by Nippon Kayaku Co. Ltd. (Tokyo, Japan). SNIPER-2 was synthesized as described previously [17]. The synthesis and structural analysis of SNIPER-4 would be reported elsewhere (Itoh et al., manuscript in preparation). cDNA encoding human CRABP-II were amplified by PCR from JHH-5 cDNA library and cloned into a p3xFLAG-CMV-10 expression vector (SIGMA). The correct DNA sequence was confirmed. The

following reagents were purchased from indicated supplier: M2 anti-FLAG mouse monoclonal antibody, M2 anti-FLAG agarose-conjugated antibody, mouse anti- $\beta$ -actin antibody (SIGMA); Fugene HD, anti-HA rat monoclonal antibody (Roche); CRABP-II antibody (Abcam); anti-human cIAP1 goat polyclonal antibody (R&D systems); anti-human XIAP mouse monoclonal antibody (MBL); Lipofectamine RNAi MAX transfection reagent, Stealth Select RNAi (Invitrogen). The target sequences for cIAP1 and XIAP RNAi were as follows: cIAP1-#1 (5'-TCTAGAGCAGTTGAAGACATCTCTT-3'); cIAP1-#2 (5'-GGAAATGCTGCGGCCAACATCTTCA-3'); XIAP-#1 (5'-ACACTGGCAGCAGCAGGTTTCTTT-3'); XIAP-#2 (5'-CCAGAATGGTCAGTACAAAAGTTGAA-3').


### 2.2. Cell culture, transfection and treatment with compounds

Human fibrosarcoma HT1080 were maintained in RPMI 1640 medium containing 10% fetal bovine serum and 100  $\mu$ g/ml of kanamycin. Transient transfections were carried out using Fugene HD according to the manufacturer's instructions. siRNA transfections were carried out by reverse transfection method with Lipofectamine RNAi MAX according to the manufacturer's instructions. In brief, 60 pmol siRNA and 3  $\mu$ l of Lipofectamine RNAi MAX were incubated in 200  $\mu$ l Opti-MEM medium for 20 min at room temperature in 12-well plates, and then 1 ml of cell suspension ( $1.5 \times 10^5$  cells) was added to the siRNA-RNAi MAX complex. HT1080 cells constitutively expressing FLAG-CRABP-II were generated and maintained in RPMI 1640 medium containing 10% fetal bovine serum and 100  $\mu$ g/ml of kanamycin and 500  $\mu$ g/ml of Geneticin (G418). The cells were treated with 10  $\mu$ M SNIPERs or vehicle (DMSO) for 6 h unless otherwise indicated, and lysed in





**Fig. 2.** (A and B) Time-course and (C) dose-dependent response of CRABP-II degradation induced by SNIPERs. HT1080 cells constitutively expressing FLAG-CRABP-II were incubated with 10  $\mu$ M compounds for indicated times (A and B), or 0.3, 1 or 3  $\mu$ M of compounds for 6 h (C, from the left of black triangle). Cell lysates were Western blotted with indicated antibodies.



**Fig. 3.** Ubiquitylation of CRABP-II induced by SNIPERs. HT1080 cells expressing FLAG-CRABP-II and HA-ubiquitin were pre-treated with MG132 for 30 min, and then incubated with 10  $\mu$ M of compounds for 1 h. Cells were lysed and FLAG-CRABP-II was immunoprecipitated with anti-FLAG antibody. The ubiquitylated CRABP-II was detected with anti-HA antibody.


lysis buffer (1% SDS, 0.1 M Tris-HCl (pH 7.0), 10% glycerol) and boiled for 10 min. Protein concentration was measured by BCA method (Pierce) and the equal amount of protein lysate was separated by SDS-PAGE, transferred to Hybond-P (GE Healthcare) membrane and Western blotted using appropriate antibody. Protein signals were detected using SuperSignal<sup>®</sup> West Femto Maximum Sensitivity Substrate (Thermo scientific) or ECL<sup>™</sup> Western Blotting Detection Reagents (GE Healthcare).

### 2.3. Ubiquitylation of CRABP-II

HA-ubiquitin was transiently transfected in HT1080 cells constitutively expressing FLAG-CRABP-II. Cells were lysed in lysis buffer and boiled, and the lysates were diluted 10 times with 0.1 M Tris-HCl. CRABP-II was immunoprecipitated with anti-FLAG agarose-conjugated beads. The immunoprecipitates were extensively washed with diluted lysis buffer, and analyzed by Western blotting using anti-HA antibody.

## 3. Results and discussion

The structures of MeBS (top), SNIPER-2 (middle) and SNIPER-4 (bottom) are shown in Fig. 1A. These SNIPERs are hybrid molecules consisting of bestatin moiety and ATRA connected by an ester-bond (SNIPER-2) or an amide-bond (SNIPER-4) spacer. SNIPER-2 induces the degradation of endogenous CRABP-II and



**Fig. 4.** Silencing of cIAP1 attenuates the SNIPER-dependent CRABP-II protein degradation. In HT1080 cells expressing FLAG-CRABP-II, the endogenous cIAP1 and XIAP were knocked down by two different siRNAs (#1 or #2) against each protein for 48 h (A). cIAP1, XIAP or both were knocked down by siRNAs (cIAP1-#1, XIAP-#2) (B). Cells were incubated with 10  $\mu$ M compounds for 6 h. Shown are immunoblots of cell lysates stained with indicated antibodies.

cIAP1 in human primary fibroblasts as we reported previously (Fig. 1B) [17]. To develop a novel SNIPER that reduces CRABP-II but not cIAP1, we designed SNIPER-4 in which the ester-bond is substituted to amide-bond, because our previous study indicated that bestatin methyl amide could bind to cIAP1 without reducing it [13]. Fig. 1C shows that the SNIPER-4 reduced the level of CRABP-II but not cIAP1 in HT1080 cells as we speculated. SNIPER-2 reduced both the CRABP-II and cIAP1, while MeBS reduced cIAP1 specifically. Likewise, in HT1080 cells expressing FLAG-tagged CRABP-II, SNIPER-4 reduced FLAG-CRABP-II but not cIAP1. The combined use of MeBS and ATRA did not induce the degradation of CRABP-II (Supplementary Fig. 1). In addition, the reduction of CRABP-II by SNIPER-4 and SNIPER-2, and that of cIAP1 by MeBS and SNIPER-2, were all abrogated by a proteasome inhibitor, MG132 (Fig. 1D). These results indicate that SNIPER-2 induces proteasomal degradation of CRABP-II and cIAP1 while SNIPER-4 degrades CRABP-II specifically, and that the linking MeBS and ATRA in one molecule is required for the CRABP-II degradation.

Then, we evaluated the effect of SNIPERs on the target protein degradation, examining the reaction time-course and the treatment dose. As shown in Fig. 2A, SNIPER-2 and -4 reduce the CRABP-II at 1 h, then kept suppressing the CRABP-II expression over 20 h. On a longer time scale, the expression levels of CRABP-II at 24 or 48 h were lower in the cells treated with SNIPER-4 than with SNIPER-2 (Fig. 2B). This may be due to the maintenance of cIAP1 level in the SNIPER-4-treated cells (Fig. 2A and B), and/or the chemical stability of SNIPER-4 compared with SNIPER-2 since ester-bond is more easily hydrolyzed than amide-bond. We also tested the dose-response of SNIPERs on CRABP-II degradation. The CRABP-II was effectively reduced by over 3  $\mu$ M and subtly

affected by 0.3  $\mu$ M or 1  $\mu$ M of SNIPER-4 (Fig. 2C and Supplementary Fig. 2).

Next, we examined whether the SNIPERs induce the ubiquitylation of CRABP-II as we assumed. Lysates from the cells expressing FLAG-tagged CRABP-II and HA-tagged ubiquitin were immunoprecipitated with anti-FLAG (CRABP-II) and the immunoprecipitates were analyzed by Western blot with anti-HA (ubiquitin) to detect the ubiquitylated CRABP-II. Smear protein bands that migrate slowly in the gels increased by SNIPER-2 and SNIPER-4 (Fig. 3), which indicates the poly-ubiquitylation of CRABP-II. We further examined whether cIAP1 is the ubiquitin ligase responsible for the degradation of CRABP-II in the SNIPER-treated cells. Silencing cIAP1 expression by siRNAs significantly suppressed the SNIPER-mediated CRABP-II degradation, whereas silencing XIAP, a close family member of cIAP1, did not (Fig. 4A and B). Expression of cIAP2, another close family member, is hardly detected in HT1080 cells (data not shown). These results indicate that cIAP1 is the primary ubiquitin ligase for CRABP-II.

Fig. 5 shows the schema of the protein knockdown by MeBS, SNIPER-2 and SNIPER-4. MeBS interacts with BIR3 domain of cIAP1 to induce auto-ubiquitylation mediated by its RING domain for proteasomal degradation (Fig. 5, top). SNIPER-2 with ester-bond cross-links cIAP1 and CRABP-II, and induces ubiquitylation of both proteins, resulting in the degradation of cIAP1 and CRABP-II by proteasome (Fig. 5, middle). SNIPER-4 with amide-bond also cross-links cIAP1 and CRABP-II, but it specifically induces proteasomal degradation of CRABP-II but not cIAP1 (Fig. 5, bottom). Thus, the amide-type SNIPER-4 would be more useful than the ester-type SNIPER-2 for protein knockdown in terms of the specificity and prolonging the duration of the degradation process.

The reason why SNIPER-4 does not degrade cIAP1 is not fully understood. We previously reported that bestatin-methyl ester (MeBS) induced proteasomal degradation of cIAP1, whereas bestatin-methyl amide (BE-04) did not [13]. Therefore, we hypothesize that BE-04 and SNIPER-4 with amide-bond would not induce auto-ubiquitylation of cIAP1, or if any it is not enough for efficient proteasomal degradation. Probably, the robustness and/or kinetics of the auto-ubiquitylation would be much lower than that induced by MeBS and SNIPER-2 with ester-bond, and therefore, de-ubiquitylation of cIAP1 quickly occurs to prevent degradation.

To study physiological functions of certain proteins, genetic knockdown by RNA interference or genetic knockout by gene targeting was commonly applied for suppressing the expression. Comparing with such genetic methods, the protein knockdown by SNIPERs has several advantages: (i) SNIPERs are small molecules and easily delivered into cells, which is especially advantageous for medical application in future. (ii) The degradation of the target protein begins soon after the addition of SNIPERs, and therefore the protein knockdown is attained in several hours. We suppose that the protein knockdown by SNIPERs could be a complementary technology to RNA interference, and if combined it may be possible to downregulate a target protein more rapidly and robustly. This is especially the case for a long-lived protein that is insufficiently downregulated by RNA interference alone.

The protein knockdown by SNIPERs depends on cIAP1-mediated ubiquitylation of the target protein. The cIAP1 is ubiquitously expressed in a variety of tissues and cells [18], indicating that the protein knockdown by SNIPERs would be attained in most tissues and cells expressing cIAP1. Since cIAP1 is involved in NF $\kappa$ B signaling in some cells, the effect of SNIPERs on normal cell function should be carefully investigated. Structurally, SNIPERs could target other proteins for degradation if ATRA is substituted to ligands for other target proteins. We propose the amide-type SNIPER could be applicable to downregulate pathogenic proteins for therapeutic purposes.






Fig. 5. Scheme of the protein knockdown by MeBS (top), SNIPER-2 (middle) and SNIPER-4 (bottom). See text for the explanation.

### Acknowledgements

We thank Nippon Kayaku Co. Ltd., for kindly providing MeBS. This study was supported in part by Grants-in-Aids for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by the research grant of Astellas Foundation for Research on Metabolic Disorders.

### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.febslet.2011.03.019.

### References

- [1] Glickman, M.H. and Ciechanover, A. (2002) The ubiquitin–proteasome proteolytic pathway: destruction for the sake of construction. *Physiol. Rev.* 82, 373–428.
- [2] Bader, M. and Steller, H. (2009) Regulation of cell death by the ubiquitin–proteasome system. *Curr. Opin. Cell Biol.* 21, 878–884.
- [3] Nakayama, K.I. and Nakayama, K. (2006) Ubiquitin ligases: cell-cycle control and cancer. *Nat. Rev. Cancer* 6, 369–381.
- [4] Jiang, Y.H. and Beaudet, A.L. (2004) Human disorders of ubiquitination and proteasomal degradation. *Curr. Opin. Pediatr.* 16, 419–426.
- [5] Zhou, X., Wang, J.L., Lu, J., Song, Y., Kwak, K.S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W.S., Lacey, D.L., Goldberg, A.L. and Han, H.Q. (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. *Cell* 142, 531–543.
- [6] Morris, L.G., Veeriah, S. and Chan, T.A. (2010) Genetic determinants at the interface of cancer and neurodegenerative disease. *Oncogene* 29, 3453–3464.
- [7] Hoeller, D., Hecker, C.M. and Dikic, I. (2006) Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. *Nat. Rev. Cancer* 6, 776–788.
- [8] Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. and Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity. *Science* 327, 1345–1350.
- [9] Sakamoto, K.M., Kim, K.B., Kumagai, A., Mercurio, F., Crews, C.M. and Deshaies, R.J. (2001) Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. *Proc. Natl. Acad. Sci. USA* 98, 8554–8559.
- [10] Srinivasula, S.M. and Ashwell, J.D. (2008) IAPs: what's in a name? *Mol. Cell* 30, 123–135.